Sec Investigation (new) — Subpoenas received late 2024 regarding August 2023 private placement and public offerings; document production completed April 2025, though investigation is not a determination of wrongdoing.

NASDAQ: TSHA Taysha Gene Therapies, Inc. 10-K

Taysha doses pivotal Rett trial patients, raises $264M, as Astellas option expires

Filed March 19, 2026 · Period ending December 31, 2025 · Compared to 10-K Feb 26, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade TSHA commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 4, 2026 6:43 AM